中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
32期
140-141,142
,共3页
奥美拉唑%克拉霉素%慢性胃炎%安全性
奧美拉唑%剋拉黴素%慢性胃炎%安全性
오미랍서%극랍매소%만성위염%안전성
Omeprazole%Clarithromycin%Chronic gastritis%Safety
目的：探讨奥美拉唑和抗生素联合治疗慢性胃炎的疗效及其安全性。方法：60例慢性胃炎的患者随机分为对照组（n=30）和观察组（n=30）。给予对照组单独口服克拉霉素治疗，给予观察组奥美拉唑和克拉霉素联合治疗，对比两组的临床症状改善情况、治疗效果及不良反应发生情况。结果：治疗后，观察组的治疗总有效率为96.67%，对照组的治疗总有效率为73.33%，两组比较差异有统计学意义（P<0.05）；观察组出现的不良反应率和对照组相比，差异无统计学意义（P>0.05）。结论：奥美拉唑和克拉霉素联合治疗的效果确切，不良反应少，值得推广。
目的：探討奧美拉唑和抗生素聯閤治療慢性胃炎的療效及其安全性。方法：60例慢性胃炎的患者隨機分為對照組（n=30）和觀察組（n=30）。給予對照組單獨口服剋拉黴素治療，給予觀察組奧美拉唑和剋拉黴素聯閤治療，對比兩組的臨床癥狀改善情況、治療效果及不良反應髮生情況。結果：治療後，觀察組的治療總有效率為96.67%，對照組的治療總有效率為73.33%，兩組比較差異有統計學意義（P<0.05）；觀察組齣現的不良反應率和對照組相比，差異無統計學意義（P>0.05）。結論：奧美拉唑和剋拉黴素聯閤治療的效果確切，不良反應少，值得推廣。
목적：탐토오미랍서화항생소연합치료만성위염적료효급기안전성。방법：60례만성위염적환자수궤분위대조조（n=30）화관찰조（n=30）。급여대조조단독구복극랍매소치료，급여관찰조오미랍서화극랍매소연합치료，대비량조적림상증상개선정황、치료효과급불량반응발생정황。결과：치료후，관찰조적치료총유효솔위96.67%，대조조적치료총유효솔위73.33%，량조비교차이유통계학의의（P<0.05）；관찰조출현적불량반응솔화대조조상비，차이무통계학의의（P>0.05）。결론：오미랍서화극랍매소연합치료적효과학절，불량반응소，치득추엄。
Objective:To investigate the efficacy and safety of omeprazole and antibiotics in treatment of chronic gastritis.Method:A total of 60 cases,of chronic gastritis patients were selected and they were randomly divided into control group(n=30)and observation group(n=30).Control group was given clarithromycin therapy,while observation group was given omeprazole and clarithromycin therapy.Clinical symptoms,overall treatment efficiency and the rate of adverse reactions in the two groups were compared.Result:The total efficiency of observation group was 96.67%,while control group was 73.33%,there was a significant different between the two group(P<0.05).The adverse reaction rate of two groups had no significant difference(P>0.05).Conclusion:Omeprazole and clarithromycin is effective with less adverse reaction,and is worthy of promoting.
